{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:08:08Z","timestamp":1788260888942,"version":"build-2803163510"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA262483"],"award-info":[{"award-number":["R01 CA262483"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R21 CA267141"],"award-info":[{"award-number":["R21 CA267141"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA076292"],"award-info":[{"award-number":["P30 CA076292"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["CA262483"],"award-info":[{"award-number":["CA262483"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA247796"],"award-info":[{"award-number":["P30 CA247796"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Melanomas can adopt multiple transcriptional states. Little is known about the epigenetic drivers of these cell states, limiting our ability to regulate melanoma heterogeneity. Here, we identify stress-induced HDAC8 activity as driving melanoma brain metastasis development. Exposure of melanocytes and melanoma cells to multiple stresses increases HDAC8 activation leading to a neural crest-stem cell transcriptional state and an amoeboid, invasive phenotype that increases seeding to the brain. Using ATAC-Seq and ChIP-Seq we show that increased HDAC8 activity alters chromatin structure by increasing H3K27ac and enhancing accessibility at c-Jun binding sites. Functionally, HDAC8 deacetylates the histone acetyltransferase EP300, causing its enzymatic inactivation. This, in turn, increases binding of EP300 to Jun-transcriptional sites and decreases binding to MITF-transcriptional sites. Inhibition of EP300 increases melanoma cell invasion, resistance to stress and increases melanoma brain metastasis development. HDAC8 is identified as a mediator of transcriptional co-factor inactivation and chromatin accessibility that drives brain metastasis.<\/jats:p>","DOI":"10.1038\/s41467-023-43519-1","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T06:02:31Z","timestamp":1701237751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["HDAC8-mediated inhibition of EP300 drives a transcriptional state that increases melanoma brain metastasis"],"prefix":"10.1038","volume":"14","author":[{"given":"Michael F.","family":"Emmons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0243-2443","authenticated-orcid":false,"given":"Richard L.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9150-8333","authenticated-orcid":false,"given":"Alberto","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanchan","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5720-5910","authenticated-orcid":false,"given":"Larissa Anastasio Da Costa","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1115-3654","authenticated-orcid":false,"given":"Robert","family":"Macaulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Dup\u00e9r\u00e9-Rich\u00e9r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7636-1318","authenticated-orcid":false,"given":"Bin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3818-1762","authenticated-orcid":false,"given":"John M.","family":"Koomen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiannong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1468-3490","authenticated-orcid":false,"given":"Y. Ann","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3756-8594","authenticated-orcid":false,"given":"Peter A.","family":"Forsyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3942-1369","authenticated-orcid":false,"given":"Jonathan D.","family":"Licht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1089-9307","authenticated-orcid":false,"given":"Keiran S. M.","family":"Smalley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"key":"43519_CR1","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1101\/gad.191999.112","volume":"26","author":"H Tsao","year":"2012","unstructured":"Tsao, H., Chin, L., Garraway, L. A. & Fisher, D. E. Melanoma: from mutations to medicine. Gene Dev. 26, 1131\u20131155 (2012).","journal-title":"Gene Dev."},{"key":"43519_CR2","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1200\/JCO.2004.08.140","volume":"22","author":"KM Fife","year":"2004","unstructured":"Fife, K. M. et al. Determinants of outcome in melanoma patients with cerebral metastases. J. Clin. Oncol. 22, 1293\u20131300 (2004).","journal-title":"J. Clin. Oncol."},{"key":"43519_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0305-7372(03)00105-1","volume":"29","author":"RA Patchell","year":"2003","unstructured":"Patchell, R. A. The management of brain metastases. Cancer Treat. Rev. 29, 533\u2013540 (2003).","journal-title":"Cancer Treat. Rev."},{"key":"43519_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.bcp.2011.09.012","volume":"83","author":"G Chen","year":"2012","unstructured":"Chen, G. & Davies, M. A. Emerging insights into the molecular biology of brain metastases. Biochem. Pharmacol. 83, 305\u2013314 (2012).","journal-title":"Biochem. Pharmacol."},{"key":"43519_CR5","doi-asserted-by":"publisher","first-page":"7538","DOI":"10.1158\/1078-0432.CCR-09-1985","volume":"15","author":"MA Davies","year":"2009","unstructured":"Davies, M. A. et al. Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin. Cancer Res. 15, 7538\u20137546 (2009).","journal-title":"Clin. Cancer Res."},{"key":"43519_CR6","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.1158\/1078-0432.CCR-13-3003","volume":"20","author":"G Chen","year":"2014","unstructured":"Chen, G. et al. Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin. Cancer Res. 20, 5537\u20135546 (2014).","journal-title":"Clin. Cancer Res."},{"key":"43519_CR7","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-14-1027","volume":"20","author":"AD Bucheit","year":"2014","unstructured":"Bucheit, A. D. et al. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB\/C melanoma patients with BRAFV600 mutations. Clin. Cancer Res. 20, 5527\u20135536 (2014).","journal-title":"Clin. Cancer Res."},{"key":"43519_CR8","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.celrep.2015.09.057","volume":"13","author":"JH Cho","year":"2015","unstructured":"Cho, J. H. et al. AKT1 activation promotes development of melanoma metastases. Cell Rep. 13, 898\u2013905 (2015).","journal-title":"Cell Rep."},{"key":"43519_CR9","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","volume":"5","author":"PK Brastianos","year":"2015","unstructured":"Brastianos, P. K. et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 5, 1164\u20131177 (2015).","journal-title":"Cancer Discov."},{"key":"43519_CR10","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1158\/2159-8290.CD-18-1489","volume":"9","author":"GM Fischer","year":"2019","unstructured":"Fischer, G. M. et al. Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases. Cancer Discov. 9, 628\u2013645 (2019).","journal-title":"Cancer Discov."},{"key":"43519_CR11","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ccell.2018.03.017","volume":"33","author":"J Tsoi","year":"2018","unstructured":"Tsoi, J. et al. Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. Cancer Cell 33, 890\u2013904 e895 (2018).","journal-title":"Cancer Cell"},{"key":"43519_CR12","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.cell.2018.06.025","volume":"174","author":"F Rambow","year":"2018","unstructured":"Rambow, F. et al. Toward minimal residual disease-directed therapy in melanoma. Cell 174, 843\u2013855.e19 (2018).","journal-title":"Cell"},{"key":"43519_CR13","doi-asserted-by":"publisher","first-page":"e145859","DOI":"10.1172\/JCI145859","volume":"131","author":"YJ Kim","year":"2021","unstructured":"Kim, Y. J. et al. Melanoma dedifferentiation induced by IFN-gamma epigenetic remodeling in response to anti-PD-1 therapy. J. Clin. Invest 131, e145859 (2021).","journal-title":"J. Clin. Invest"},{"key":"43519_CR14","doi-asserted-by":"publisher","first-page":"13679","DOI":"10.1073\/pnas.1712064115","volume":"114","author":"Y Su","year":"2017","unstructured":"Su, Y. et al. Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance. Proc. Natl. Acad. Sci. USA 114, 13679\u201313684 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"43519_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6712","volume":"5","author":"J Muller","year":"2014","unstructured":"Muller, J. et al. Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat. Commun. 5, 5712 (2014).","journal-title":"Nat. Commun."},{"key":"43519_CR16","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41586-022-05242-7","volume":"610","author":"P Karras","year":"2022","unstructured":"Karras, P. et al. A cellular hierarchy in melanoma uncouples growth and metastasis. Nature 610, 190\u2013198 (2022).","journal-title":"Nature"},{"key":"43519_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2016.06.014","volume":"15","author":"MF Emmons","year":"2016","unstructured":"Emmons, M. F., Faiao-Flores, F. & Smalley, K. S. The role of phenotypic plasticity in the escape of cancer cells from targeted therapy. Biochem. Pharm. 15, 1\u20139 (2016).","journal-title":"Biochem. Pharm."},{"key":"43519_CR18","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ebiom.2019.09.023","volume":"48","author":"I Smalley","year":"2019","unstructured":"Smalley, I. et al. Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma. EBioMedicine 48, 178\u2013190 (2019).","journal-title":"EBioMedicine"},{"key":"43519_CR19","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1158\/2159-8290.CD-13-0424","volume":"4","author":"DJ Konieczkowski","year":"2014","unstructured":"Konieczkowski, D. J. et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 4, 816\u2013827 (2014).","journal-title":"Cancer Discov."},{"key":"43519_CR20","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1158\/0008-5472.CAN-19-0040","volume":"79","author":"MF Emmons","year":"2019","unstructured":"Emmons, M. F. et al. HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy. Cancer Res 79, 2947\u20132961 (2019).","journal-title":"Cancer Res"},{"key":"43519_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nature11316","volume":"489","author":"MA Deardorff","year":"2012","unstructured":"Deardorff, M. A. et al. HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle. Nature 489, 313\u2013317 (2012).","journal-title":"Nature"},{"key":"43519_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/exd.14286","volume":"31","author":"M Phadke","year":"2022","unstructured":"Phadke, M., Ozgun, A., Eroglu, Z. & Smalley, K. S. M. Melanoma brain metastases: Biological basis and novel therapeutic strategies. Exp. Dermatol 31, 31\u201342 (2022).","journal-title":"Exp. Dermatol"},{"key":"43519_CR23","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.cell.2014.01.040","volume":"156","author":"M Valiente","year":"2014","unstructured":"Valiente, M. et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 156, 1002\u20131016 (2014).","journal-title":"Cell"},{"key":"43519_CR24","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nm.2072","volume":"16","author":"Y Kienast","year":"2010","unstructured":"Kienast, Y. et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat. Med. 16, 116\u2013122 (2010).","journal-title":"Nat. Med."},{"key":"43519_CR25","first-page":"773","volume":"45","author":"IJ Fidler","year":"1970","unstructured":"Fidler, I. J. Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2\u2019-deoxyuridine. J. Natl. Cancer Inst. 45, 773\u2013782 (1970).","journal-title":"J. Natl. Cancer Inst."},{"key":"43519_CR26","doi-asserted-by":"publisher","first-page":"e50973","DOI":"10.1371\/journal.pone.0050973","volume":"7","author":"JM Barnes","year":"2012","unstructured":"Barnes, J. M., Nauseef, J. T. & Henry, M. D. Resistance to fluid shear stress is a conserved biophysical property of malignant cells. PLoS One 7, e50973 (2012).","journal-title":"PLoS One"},{"key":"43519_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/1478-811X-12-24","volume":"12","author":"ML Taddei","year":"2014","unstructured":"Taddei, M. L. et al. Mesenchymal to amoeboid transition is associated with stem-like features of melanoma cells. Cell Commun. Signal 12, 24 (2014).","journal-title":"Cell Commun. Signal"},{"key":"43519_CR28","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1158\/1078-0432.CCR-21-1694","volume":"27","author":"I Smalley","year":"2021","unstructured":"Smalley, I. et al. Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases. Clin. Cancer Res 27, 4109\u20134125 (2021).","journal-title":"Clin. Cancer Res"},{"key":"43519_CR29","doi-asserted-by":"publisher","unstructured":"Eroglu Z. et al. Combined BRAF, MEK, and heat-shock protein 90 (HSP90) inhibition in advanced BRAF V600-mutant melanoma. Cancer https:\/\/doi.org\/10.1002\/cncr.35029 (2023).","DOI":"10.1002\/cncr.35029"},{"key":"43519_CR30","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1158\/2159-8290.CD-21-0385","volume":"12","author":"AD Durbin","year":"2022","unstructured":"Durbin, A. D. et al. EP300 selectively controls the enhancer landscape of MYCN-amplified neuroblastoma. Cancer Discov. 12, 730\u2013751 (2022).","journal-title":"Cancer Discov."},{"key":"43519_CR31","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.molcel.2020.05.025","volume":"79","author":"P Louphrasitthiphol","year":"2020","unstructured":"Louphrasitthiphol, P. et al. Tuning transcription factor availability through acetylation-mediated genomic redistribution. Mol. Cell 79, 472\u2013487 e410 (2020).","journal-title":"Mol. Cell"},{"key":"43519_CR32","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1101\/gad.1809209","volume":"23","author":"M Haberland","year":"2009","unstructured":"Haberland, M., Mokalled, M. H., Montgomery, R. L. & Olson, E. N. Epigenetic control of skull morphogenesis by histone deacetylase 8. Genes Dev. 23, 1625\u20131630 (2009).","journal-title":"Genes Dev."},{"key":"43519_CR33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrg2485","volume":"10","author":"M Haberland","year":"2009","unstructured":"Haberland, M., Montgomery, R. L. & Olson, E. N. The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. Nat. Rev. Genet 10, 32\u201342 (2009).","journal-title":"Nat. Rev. Genet"},{"key":"43519_CR34","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1182\/blood.2019003538","volume":"135","author":"J Long","year":"2020","unstructured":"Long, J. et al. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia. Blood 135, 1472\u20131483 (2020).","journal-title":"Blood"},{"key":"43519_CR35","doi-asserted-by":"publisher","first-page":"12761","DOI":"10.1074\/jbc.M115.704627","volume":"291","author":"T Dasgupta","year":"2016","unstructured":"Dasgupta, T., Antony, J., Braithwaite, A. W. & Horsfield, J. A. HDAC8 inhibition blocks SMC3 deacetylation and delays cell cycle progression without affecting cohesin-dependent transcription in MCF7 cancer cells. J. Biol. Chem. 291, 12761\u201312770 (2016).","journal-title":"J. Biol. Chem."},{"key":"43519_CR36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/1078-0432.CCR-08-0684","volume":"15","author":"I Oehme","year":"2009","unstructured":"Oehme, I. et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin. Cancer Res. 15, 91\u201399 (2009).","journal-title":"Clin. Cancer Res."},{"key":"43519_CR37","doi-asserted-by":"publisher","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","volume":"6","author":"E Seto","year":"2014","unstructured":"Seto, E. & Yoshida, M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb. Perspect. Biol. 6, a018713 (2014).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"43519_CR38","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1128\/MCB.24.2.765-773.2004","volume":"24","author":"H Lee","year":"2004","unstructured":"Lee, H., Rezai-Zadeh, N. & Seto, E. Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A. Mol. Cell Biol. 24, 765\u2013773 (2004).","journal-title":"Mol. Cell Biol."},{"key":"43519_CR39","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/onc.2012.81","volume":"32","author":"W Yan","year":"2013","unstructured":"Yan, W. et al. Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene 32, 599\u2013609 (2013).","journal-title":"Oncogene"},{"key":"43519_CR40","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1182\/blood-2017-03-771386","volume":"130","author":"WK Hua","year":"2017","unstructured":"Hua, W. K. et al. HDAC8 regulates long-term hematopoietic stem-cell maintenance under stress by modulating p53 activity. Blood 130, 2619\u20132630 (2017).","journal-title":"Blood"},{"key":"43519_CR41","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/cncr.25634","volume":"117","author":"MA Davies","year":"2011","unstructured":"Davies, M. A. et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117, 1687\u20131696 (2011).","journal-title":"Cancer"},{"key":"43519_CR42","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1016\/j.cell.2022.06.007","volume":"185","author":"J Biermann","year":"2022","unstructured":"Biermann, J. et al. Dissecting the treatment-naive ecosystem of human melanoma brain metastasis. Cell 185, 2591\u20132608 e2530 (2022).","journal-title":"Cell"},{"key":"43519_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7683","volume":"6","author":"A Verfaillie","year":"2015","unstructured":"Verfaillie, A. et al. Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. Nat. Commun. 6, 6683 (2015).","journal-title":"Nat. Commun."},{"key":"43519_CR44","doi-asserted-by":"publisher","first-page":"ra82","DOI":"10.1126\/scisignal.aab1111","volume":"8","author":"R Ramsdale","year":"2015","unstructured":"Ramsdale, R. et al. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. Sci. Signal 8, ra82 (2015).","journal-title":"Sci. Signal"},{"key":"43519_CR45","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1021\/acschembio.6b00396","volume":"11","author":"P Aramsangtienchai","year":"2016","unstructured":"Aramsangtienchai, P. et al. HDAC8 catalyzes the hydrolysis of long chain fatty acyl lysine. ACS Chem. Biol. 11, 2685\u20132692 (2016).","journal-title":"ACS Chem. Biol."},{"key":"43519_CR46","doi-asserted-by":"publisher","first-page":"a026534","DOI":"10.1101\/cshperspect.a026534","volume":"7","author":"N Attar","year":"2017","unstructured":"Attar, N. & Kurdistani, S. K. Exploitation of EP300 and CREBBP lysine acetyltransferases by cancer. Cold Spring Harb. Perspect. Med. 7, a026534 (2017).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"43519_CR47","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/20974","volume":"399","author":"C Dhalluin","year":"1999","unstructured":"Dhalluin, C. et al. Structure and ligand of a histone acetyltransferase bromodomain. Nature 399, 491\u2013496 (1999).","journal-title":"Nature"},{"key":"43519_CR48","doi-asserted-by":"publisher","first-page":"14789","DOI":"10.1073\/pnas.232568499","volume":"99","author":"VI Rebel","year":"2002","unstructured":"Rebel, V. I. et al. Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc. Natl. Acad. Sci. USA 99, 14789\u201314794 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"43519_CR49","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.immuni.2019.08.006","volume":"51","author":"SN Meyer","year":"2019","unstructured":"Meyer, S. N. et al. Unique and shared epigenetic programs of the CREBBP and EP300 acetyltransferases in germinal center B cells reveal targetable dependencies in lymphoma. Immunity 51, 535\u2013547 e539 (2019).","journal-title":"Immunity"},{"key":"43519_CR50","doi-asserted-by":"publisher","first-page":"5396","DOI":"10.1093\/nar\/gkq184","volume":"38","author":"YF Ramos","year":"2010","unstructured":"Ramos, Y. F. et al. Genome-wide assessment of differential roles for p300 and CBP in transcription regulation. Nucleic Acids Res. 38, 5396\u20135408 (2010).","journal-title":"Nucleic Acids Res"},{"key":"43519_CR51","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12860-020-00296-9","volume":"21","author":"S Martire","year":"2020","unstructured":"Martire, S., Nguyen, J., Sundaresan, A. & Banaszynski, L. A. Differential contribution of p300 and CBP to regulatory element acetylation in mESCs. BMC Mol. Cell Biol. 21, 55 (2020).","journal-title":"BMC Mol. Cell Biol."},{"key":"43519_CR52","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.molcel.2008.09.018","volume":"32","author":"JC Black","year":"2008","unstructured":"Black, J. C., Mosley, A., Kitada, T., Washburn, M. & Carey, M. The SIRT2 deacetylase regulates autoacetylation of p300. Mol. Cell 32, 449\u2013455 (2008).","journal-title":"Mol. Cell"},{"key":"43519_CR53","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/nsmb740","volume":"11","author":"PR Thompson","year":"2004","unstructured":"Thompson, P. R. et al. Regulation of the p300 HAT domain via a novel activation loop. Nat. Struct. Mol. Biol. 11, 308\u2013315 (2004).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"43519_CR54","doi-asserted-by":"publisher","first-page":"6095","DOI":"10.1093\/emboj\/20.21.6095","volume":"20","author":"RG Vries","year":"2001","unstructured":"Vries, R. G. et al. A specific lysine in c-Jun is required for transcriptional repression by E1A and is acetylated by p300. EMBO J. 20, 6095\u20136103 (2001).","journal-title":"EMBO J."},{"key":"43519_CR55","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.bbagrm.2013.07.007","volume":"1829","author":"D Zhang","year":"2013","unstructured":"Zhang, D., Suganuma, T. & Workman, J. L. Acetylation regulates Jun protein turnover in Drosophila. Biochim. Biophys. Acta 1829, 1218\u20131224 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"43519_CR56","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.CD-14-0293","volume":"5","author":"KH Paraiso","year":"2015","unstructured":"Paraiso, K. H. et al. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov. 5, 264\u2013273 (2015).","journal-title":"Cancer Discov."},{"key":"43519_CR57","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/nmeth.3542","volume":"12","author":"C Schmidl","year":"2015","unstructured":"Schmidl, C., Rendeiro, A. F., Sheffield, N. C. & Bock, C. ChIPmentation: Fast, robust, low-input ChIP-seq for histones and transcription factors. Nat. Methods 12, 963\u2013965 (2015).","journal-title":"Nat. Methods"},{"key":"43519_CR58","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/nmeth.2688","volume":"10","author":"JD Buenrostro","year":"2013","unstructured":"Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y. & Greenleaf, W. J. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat. Methods 10, 1213\u20131218 (2013).","journal-title":"Nat. Methods"},{"key":"43519_CR59","doi-asserted-by":"publisher","unstructured":"Riva A. HDAC8-mediated inhibition of EP300 drives a transcriptional state that increases melanoma brain metastasis. https:\/\/doi.org\/10.5281\/zenodo.8381172, (2023).","DOI":"10.5281\/zenodo.8381172"},{"key":"43519_CR60","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/nbt.1511","volume":"26","author":"J Cox","year":"2008","unstructured":"Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367\u20131372 (2008).","journal-title":"Nat. Biotechnol."},{"key":"43519_CR61","doi-asserted-by":"crossref","unstructured":"Welsh E. A., Eschrich S. A., Berglund A. E., Fenstermacher D. A. Iterative rank-order normalization of gene expression microarray data. BMC Bioinformatics 14, 153 (2013).","DOI":"10.1186\/1471-2105-14-153"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-43519-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-43519-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-43519-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T06:04:04Z","timestamp":1701237844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-43519-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["43519"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-43519-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,29]]},"assertion":[{"value":"24 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.A.F. serves on advisory boards for AbbVie Inc., Bristol-Myers Squibb, Boehringer-Ingelheim, NCI Neuro-Oncology Branch Peer Review, NCRI, NIH, Novellus, Physical Sciences Oncology Network, Tocagen (not active), Ziopharm, National Brain Tumor Society and as a consultant for Bayer, BTG, GlaxoSmithKline (GSK), Inovio, and Novocure. KSMS receives grant funding from Revolution Medicines and honoraria from Elsevier unrelated to the current study. J.M.K. receives salary support from BMS. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7759"}}